2,329.00
+20(+0.87%)
Currency In JPY
Address
Nihonbashi-Honcho YS Building
Tokyo, 103-0023
Japan
Phone
81 3 6214 3600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
867
First IPO Date
August 31, 2007
| Name | Title | Pay | Year Born |
| Dr. Ying Luo Ph.D. | Chief Executive Officer, President, Representative Executive Officer & Chair | 70.56M | 1965 |
| Mr. Zhang Ping | Executive Officer & Independent Outside Director | 0 | 1973 |
| Dr. Cristin Print | Co-Founder | 0 | N/A |
| Mr. Takuya Kaneko L.L.M. | Executive Officer & Chief Strategy Officer | 0 | N/A |
| Prof. Kan-ichiro Suzuki Ph.D. | Vice President & Executive Officer | 0 | 1954 |
| Kazuhiro Kawauchi | Executive Officer & Chief Business Development Officer | 0 | 1962 |
| Dr. Kosuke Tashiro | Co-Founder | 0 | N/A |
| Dr. Stephen Charnock-Jones | Co-Founder | 0 | N/A |
| Mr. Ryosuke Matsui | Executive Officer, Vice President, Chief Operating Officer, Chief Financial Officer & Independent Outside Director | 0 | 1979 |
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.